Post-marketing surveillance of carfilzomib in Japanese patients with relapsed or refractory multiple myeloma
| Autor: | Akira Kawasaki, Hirokazu Murakami, Takaaki Chou, Masaru Matsushita, Masahiro Kizaki |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Future Oncology. 18:2661-2674 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Carfilzomib is a medicine that was recently approved for the treatment of cancer of bone marrow (multiple myeloma) that comes back or does not respond to previous treatment (relapsed or refractory). Data gathered from the hospitals, where the medicine is commonly used, was used to generate evidence. We looked at how well carfilzomib works in Japanese participants and if it is safe. Overall, 63.5% of participants treated with carfilzomib had side effects and 37.7% had serious side effects. Death occurred in 3.1% of participants during the study. Decrease in bone marrow and blood cells, infections, heart and kidney disorder, liver failure or dysfunction, and high blood pressure occurred in 5% or more participants. In 46.5% of participants the tumors had disappeared or shrank. In Japanese participants, carfilzomib was found to be safe and effective treatment for cancer of bone marrow that comes back or does not respond to previous treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|